EE200000147A - April - uus kasvuefekte omav valk - Google Patents

April - uus kasvuefekte omav valk

Info

Publication number
EE200000147A
EE200000147A EEP200000147A EEP200000147A EE200000147A EE 200000147 A EE200000147 A EE 200000147A EE P200000147 A EEP200000147 A EE P200000147A EE P200000147 A EEP200000147 A EE P200000147A EE 200000147 A EE200000147 A EE 200000147A
Authority
EE
Estonia
Prior art keywords
april
new growth
growth protein
protein
new
Prior art date
Application number
EEP200000147A
Other languages
English (en)
Estonian (et)
Inventor
Tschopp Jurg
Original Assignee
Biogen, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Incorporated filed Critical Biogen, Incorporated
Publication of EE200000147A publication Critical patent/EE200000147A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EEP200000147A 1997-09-12 1998-09-11 April - uus kasvuefekte omav valk EE200000147A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5878697P 1997-09-12 1997-09-12
US7938498P 1998-03-26 1998-03-26
PCT/US1998/019191 WO1999012965A2 (en) 1997-09-12 1998-09-11 April- a novel protein with growth effects

Publications (1)

Publication Number Publication Date
EE200000147A true EE200000147A (et) 2001-02-15

Family

ID=26738027

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000147A EE200000147A (et) 1997-09-12 1998-09-11 April - uus kasvuefekte omav valk

Country Status (20)

Country Link
US (3) US20030138884A1 (enExample)
EP (1) EP1027431A2 (enExample)
JP (1) JP2001515712A (enExample)
KR (1) KR100618492B1 (enExample)
CN (1) CN1195849C (enExample)
AU (1) AU759717B2 (enExample)
BR (1) BR9812634A (enExample)
CA (1) CA2303615A1 (enExample)
CZ (1) CZ294615B6 (enExample)
EA (1) EA005411B1 (enExample)
EE (1) EE200000147A (enExample)
HU (1) HUP0004611A3 (enExample)
IL (1) IL134537A0 (enExample)
IS (1) IS5378A (enExample)
NO (1) NO20001242L (enExample)
NZ (1) NZ503850A (enExample)
PL (1) PL339463A1 (enExample)
SK (1) SK3542000A3 (enExample)
TR (1) TR200000669T2 (enExample)
WO (1) WO1999012965A2 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
WO1999050416A1 (en) * 1997-09-30 1999-10-07 Pharmacia & Upjohn Company Tnf-related death ligand
WO1999026976A1 (en) * 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
ES2204528T3 (es) 1999-01-25 2004-05-01 Biogen, Inc. Baff, sus inhibidores y su uso en la modulacion de la respuesta de las celulas b.
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
JP4787439B2 (ja) * 1999-08-17 2011-10-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド 免疫調節因子であるｂａｆｆレセプター（ｂｃｍａ）
UA74798C2 (uk) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
WO2001025256A2 (en) * 1999-10-06 2001-04-12 University Of Utah Research Foundation Trdl-1-gamma, a novel tumor necrosis-like ligand
AU3495301A (en) 2000-02-11 2001-08-20 Biogen Inc Heterologous polypeptide of the tnf family
IL150755A0 (en) * 2000-02-16 2003-02-12 Genentech Inc Uses of agonists and antagonists to modulate activity of tnf-related molecules
AU2006201471B2 (en) * 2000-02-16 2009-07-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of TNF-related molecules
AU2001263114A1 (en) * 2000-05-12 2001-11-26 Amgen Inc Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
CA2413160A1 (en) * 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
GB2370273A (en) * 2000-12-20 2002-06-26 Viaxxel Biotech Gmbh Compounds that affect CD83 expression
ATE446771T1 (de) 2001-05-24 2009-11-15 Zymogenetics Inc Taci-immunoglobulin-fusionsproteine
JP2004537290A (ja) 2001-05-24 2004-12-16 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 腫瘍壊死因子δ（ＡＰＲＩＬ）に対する抗体
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
WO2003057856A2 (en) 2002-01-04 2003-07-17 Xencor Dominant negative proteins and methods thereof
WO2004089982A2 (en) * 2003-01-06 2004-10-21 Xencor April variants and methods thereof
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
NZ543174A (en) 2003-03-28 2008-09-26 Biogen Idec Inc Truncated BAFF receptors
JP2008505607A (ja) * 2004-01-29 2008-02-28 ジェネンテック・インコーポレーテッド Ｂｃｍａの細胞外ドメインの変異体とその使用法
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
WO2005113598A2 (en) * 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
JP2008525002A (ja) 2004-12-23 2008-07-17 ラボラトワール セローノ ソシエテ アノニム Ｂｃｍａポリペプチド及びその使用
CA2618765A1 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for treating b-cell malignancies using taci-ig fusion molecule
US8808696B2 (en) 2005-08-09 2014-08-19 Ares Trading S.A. Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
ATE500275T1 (de) * 2005-09-26 2011-03-15 Enzo Life Sciences Els Ag Antikörper gegen april als biomarker zur frühen prognose in lymphompatienten
AU2006344395B2 (en) 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
AR060935A1 (es) 2006-05-15 2008-07-23 Ares Trading Sa Metodos para tratar enfermedades autoinmunes utilizando una molecula de fusion taci- ig
PL2403528T3 (pl) 2009-03-02 2017-08-31 Aduro Biotech Holdings, Europe B.V. Przeciwciała przeciwko ligandowi indukującemu proliferację (APRIL)
EP2542679A1 (en) * 2010-03-05 2013-01-09 Academisch Medisch Centrum bij de Universiteit van Amsterdam B-cell stimulating fusion proteins of an antigen with baff or april
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
NL2011406C2 (en) * 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
PT4269430T (pt) * 2013-09-23 2025-08-06 Regeneron Pharma Animais não-humanos com um gene humanizado de proteína reguladora de sinal
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
EP3071025B1 (en) * 2013-11-19 2018-10-10 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized a proliferation-inducing ligand gene
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
CN109089419B (zh) 2015-11-25 2024-03-01 威特拉公司 April的抗体分子及其应用
US11484027B2 (en) 2020-10-29 2022-11-01 Industrial Polymers and Chemicals, Inc. Air filter with pathogen monitoring and inactivation
WO2023019223A2 (en) 2021-08-11 2023-02-16 Akso Biopharmaceutical Inc. METHODS OF REDUCING PRODUCTION OF IgA, IgM AND/OR IgG USING sBCMA VARIANTS AND FC FUSION PROTEINS THEREOF
US12173081B2 (en) 2023-03-21 2024-12-24 Biograph 55, Inc. CD19/CD38 multispecific antibodies
CN118909083A (zh) * 2024-07-30 2024-11-08 江苏省农业科学院 一种猪b细胞增殖诱导配体蛋白及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5176996A (en) * 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) * 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) * 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
WO1996040774A1 (en) * 1995-06-07 1996-12-19 Biogen, Inc. Complexes of modified lymphotoxins as pharmaceutical preparations
ATE254135T1 (de) * 1996-03-14 2003-11-15 Human Genome Sciences Inc Humaner tumornekrosefaktor delta und epsilon
US6509170B1 (en) * 1996-03-14 2003-01-21 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor delta
US6171787B1 (en) * 1997-06-26 2001-01-09 Abbott Laboratories Member of the TNF family useful for treatment and diagnosis of disease

Also Published As

Publication number Publication date
NO20001242D0 (no) 2000-03-09
AU759717B2 (en) 2003-04-17
EA005411B1 (ru) 2005-02-24
CN1270632A (zh) 2000-10-18
WO1999012965A3 (en) 1999-06-03
PL339463A1 (en) 2000-12-18
JP2001515712A (ja) 2001-09-25
NZ503850A (en) 2002-12-20
CZ294615B6 (cs) 2005-02-16
EA200000310A1 (ru) 2000-10-30
WO1999012965A2 (en) 1999-03-18
KR100618492B1 (ko) 2006-08-31
HUP0004611A3 (en) 2002-04-29
CN1195849C (zh) 2005-04-06
SK3542000A3 (en) 2000-08-14
AU9316298A (en) 1999-03-29
IS5378A (is) 2000-02-18
BR9812634A (pt) 2000-08-22
KR20010023893A (ko) 2001-03-26
US20050112596A1 (en) 2005-05-26
CA2303615A1 (en) 1999-03-18
US20060084148A1 (en) 2006-04-20
HUP0004611A2 (hu) 2001-04-28
EP1027431A2 (en) 2000-08-16
IL134537A0 (en) 2001-04-30
US20030138884A1 (en) 2003-07-24
NO20001242L (no) 2000-05-11
TR200000669T2 (tr) 2000-08-21
CZ2000869A3 (cs) 2000-09-13

Similar Documents

Publication Publication Date Title
EE200000147A (et) April - uus kasvuefekte omav valk
NO983364D0 (no) Konsensusproteiner
DE59806239D1 (de) Mähdrescher
EP0913086A4 (en) BAIT
NO2010022I2 (no) Denosumab
DE69839603D1 (de) Zierenden proteins
DE69820156D1 (de) VErbessertes monofilament
DE69824232D1 (de) Gefriergerät
DE69802241D1 (de) Mähmaschine
DE59706733D1 (de) Erntemaschine
DK0832553T3 (da) Mejetærsker
DE59705517D1 (de) Mähdrescher
EP1018551A4 (en) MEGSIN PROTEIN
FR2747908B1 (fr) Suture irrigatrice
ID22391A (id) Alat pendingin
ATE295417T1 (de) Angiostatin-bindendes protein
TR199701666A3 (tr) Sismanliga karsi proteinler
DE59808209D1 (de) Mähdrescher
DE59809449D1 (de) Mähdrescher
DE69636232D1 (de) Wachstumsfaktor htter36
ATA126198A (de) Mähwerk
DE69801101D1 (de) Kraftzange
DK1088069T3 (da) Angiostatin-bindende protein
SE9802189D0 (sv) New Proteins
KR970056464U (ko) 개량 낚시

Legal Events

Date Code Title Description
HC1A Change of owner name